Literature DB >> 17056545

Epigenetic histone modifications do not control Igkappa locus contraction and intranuclear localization in cells with dual B cell-macrophage potential.

Suchita Hodawadekar1, Fang Wei, Duonan Yu, Andrei Thomas-Tikhonenko, Michael L Atchison.   

Abstract

Somatic rearrangement of the Ig genes during B cell development is believed to be controlled, at least in part, by accessibility of the loci to the recombinational machinery. Accessibility is poorly understood, but appears to be controlled by a combination of histone posttranslational modifications, large scale Ig locus contractions, and changes in intranuclear localization of the loci. These changes are regulated by developmental stage-specific as well as tissue-specific mechanisms. We previously isolated a murine B cell lymphoma line, Myc5, that can oscillate between the B cell and macrophage lineages depending upon growth conditions. This line provides an opportunity to study tissue-specific regulation of epigenetic mechanisms operating on the Ig loci. We found that when Myc5 cells are induced to differentiate from B cells into macrophages, expression of macrophage-specific transcripts was induced (M-CSFR, F4/80, and CD14), whereas B cell-specific transcripts decreased dramatically (mb-1, E47, IRF4, Pax5, and Igkappa). Loss of Igkappa transcription was associated with reduced Igkappa locus contraction, as well as increased association with heterochromatin protein-1 and association of the Igkappa locus with the nuclear periphery. Surprisingly, however, we found that histone modifications at the Igkappa locus remained largely unchanged whether the cells were grown in vivo as B cells, or in vitro as macrophages. These results mechanistically uncouple histone modifications at the Igkappa locus from changes in locus contraction and intranuclear localization.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17056545      PMCID: PMC1635549          DOI: 10.4049/jimmunol.177.9.6165

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  38 in total

1.  Epigenetic ontogeny of the Igk locus during B cell development.

Authors:  Maya Goldmit; Yanhong Ji; Jane Skok; Esther Roldan; Steffen Jung; Howard Cedar; Yehudit Bergman
Journal:  Nat Immunol       Date:  2004-12-26       Impact factor: 25.606

Review 2.  Evidence for a developmental relationship between CD5+ B-lineage cells and macrophages.

Authors:  W F Davidson; J H Pierce; K L Holmes
Journal:  Ann N Y Acad Sci       Date:  1992-05-04       Impact factor: 5.691

3.  Fibroblasts support outgrowth of splenocytes simultaneously expressing B lymphocyte and macrophage characteristics.

Authors:  M A Borrello; R P Phipps
Journal:  J Immunol       Date:  1995-11-01       Impact factor: 5.422

4.  A two-step mechanism for recruitment of Pip by PU.1.

Authors:  J M Perkel; M L Atchison
Journal:  J Immunol       Date:  1998-01-01       Impact factor: 5.422

5.  PU.1 can participate in an active enhancer complex without its transcriptional activation domain.

Authors:  J M Pongubala; M L Atchison
Journal:  Proc Natl Acad Sci U S A       Date:  1997-01-07       Impact factor: 11.205

6.  Effect of PU.1 phosphorylation on interaction with NF-EM5 and transcriptional activation.

Authors:  J M Pongubala; C Van Beveren; S Nagulapalli; M J Klemsz; S R McKercher; R A Maki; M L Atchison
Journal:  Science       Date:  1993-03-12       Impact factor: 47.728

7.  A novel cellular model (SPGM 1) of switching between the pre-B cell and myelomonocytic lineages.

Authors:  M Martin; A Strasser; N Baumgarth; F M Cicuttini; K Welch; E Salvaris; A W Boyd
Journal:  J Immunol       Date:  1993-05-15       Impact factor: 5.422

8.  Transcription factor Pip can enhance DNA binding by E47, leading to transcriptional synergy involving multiple protein domains.

Authors:  S Nagulapalli; M L Atchison
Journal:  Mol Cell Biol       Date:  1998-08       Impact factor: 4.272

9.  Locus 'decontraction' and centromeric recruitment contribute to allelic exclusion of the immunoglobulin heavy-chain gene.

Authors:  Esther Roldán; Martin Fuxa; Winnie Chong; Dolores Martinez; Maria Novatchkova; Meinrad Busslinger; Jane A Skok
Journal:  Nat Immunol       Date:  2004-12-05       Impact factor: 31.250

10.  Dynamic regulation of PU.1 expression in multipotent hematopoietic progenitors.

Authors:  Stephen L Nutt; Donald Metcalf; Angela D'Amico; Matthew Polli; Li Wu
Journal:  J Exp Med       Date:  2005-01-17       Impact factor: 14.307

View more
  4 in total

1.  Immunoglobulin kappa enhancers are differentially regulated at the level of chromatin structure.

Authors:  Barbara S Nikolajczyk; Sylvia H Sardi; Joseph R Tumang; Lisa M Ganley-Leal
Journal:  Mol Immunol       Date:  2007-03-26       Impact factor: 4.407

2.  CD19 is a major B cell receptor-independent activator of MYC-driven B-lymphomagenesis.

Authors:  Elaine Y Chung; James N Psathas; Duonan Yu; Yimei Li; Mitchell J Weiss; Andrei Thomas-Tikhonenko
Journal:  J Clin Invest       Date:  2012-05-01       Impact factor: 14.808

3.  B-Lymphoma cells with epigenetic silencing of Pax5 trans-differentiate into macrophages, but not other hematopoietic lineages.

Authors:  Suchita Hodawadekar; Duonan Yu; Diana Cozma; Bruce Freedman; Oriol Sunyer; Michael L Atchison; Andrei Thomas-Tikhonenko
Journal:  Exp Cell Res       Date:  2006-10-25       Impact factor: 3.905

4.  B cell activator PAX5 promotes lymphomagenesis through stimulation of B cell receptor signaling.

Authors:  Diana Cozma; Duonan Yu; Suchita Hodawadekar; Anna Azvolinsky; Shannon Grande; John W Tobias; Michele H Metzgar; Jennifer Paterson; Jan Erikson; Teresa Marafioti; John G Monroe; Michael L Atchison; Andrei Thomas-Tikhonenko
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.